Nasopharyngeal cancer

Potential treatment options for rare cancer

Researchers have found that a combination of chemotherapy and modern radiotherapy can benefit patients with advanced nasopharyngeal cancer – a cancer that starts at the back of the nose. These cancers are very rare in the UK and so modern treatments had not been previously studied in patients with advanced disease.

Researchers assessed patients who received the chemotherapy drugs cisplatin and...
Researchers assessed patients who received the chemotherapy drugs cisplatin and fluorouracil combined with intensity-modulated radiotherapy (IMRT), above.
Source: ICR/Jan Chlebik

In Europe, around one in every 100,000 people will get nasopharyngeal cancer each year. This rare cancer develops where the nose meets the throat, making it difficult to treat. Using a beam of radiation therapy to treat the cancer can risk harming healthy tissue in the brain, optic nerves and salivary glands. Many patients treated with conventional radiotherapy will be left with damaged saliva flow and a long-term dry mouth.

Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust assessed 42 nasopharyngeal cancer patients who received the chemotherapy drugs cisplatin and fluorouracil combined with intensity-modulated radiotherapy (IMRT).

IMRT is an advanced radiotherapy technique that shapes the radiation beams to closely fit the area of the cancer and avoid healthy tissue. The researchers hoped that this would help to protect the salivary glands that were often damaged with conventional therapy.
Benefits for patients

The researchers compared their results with outcomes from current treatment for advanced and early stages of the disease. They found that the chemotherapy and IMRT combination provided benefits for patients.

Study leader Professor Kevin Harrington, Joint Head of the ICR’s Division of Radiotherapy and Imaging, said: “In the two years following treatment, 78% of the patients experienced no further progress of their disease. What’s more, we saw excellent recovery of salivary function. Conventional radiotherapy can damage salivary glands and leave patients with long-term damage. This new technique used more accurate radiotherapy beams to protect healthy tissue.”

“With rare cancers, we are unable to get the numbers of patients needed for large scale clinical trials of new therapies, so I am always delighted to see positive results from this type of analysis that could help to improve treatment,” said Professor Harrington.


Source: ICR - The Institute of Cancer Research

06.04.2016

Read all latest stories

Related articles

Photo

"Bless you!"

Common cold virus could revolutionise bladder cancer treatment

A strain of the common cold virus has been found to potentially target, infect and destroy cancer cells in patients with bladder cancer. No trace of the cancer was found in one patient following…

Photo

Therapeutic progress

Cancer: riding the wave of innovation

In haematology and medical oncology, there is always something new. However, the increasing stratification of cancer therapies presents an enormous challenge for clinical research. Tumour cells –…

Photo

Glioblastoma

New actively personalized therapeutic vaccine for brain cancer

The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the recent publication in Nature of favorable data from the phase 1 study GAPVAC-101,…

Related products

Block Imaging

Surgical II-C-Arms

Block Imaging

Block Imaging
Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+

Single Plane

Canon – Alphenix Core+

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+

Single Plane

Canon – Alphenix Core+

Canon Medical Systems Europe B.V.
Canon – Alphenix Hybrid

Single Plane

Canon – Alphenix Hybrid

Canon Medical Systems Europe B.V.
Canon – Alphenix Hybrid+

Single Plane

Canon – Alphenix Hybrid+

Canon Medical Systems Europe B.V.